Navigation Links
Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients

is needed or a different dose schedule.

Because BARACLUDE is removed from the body through the kidneys, a lower dose or a different dose schedule may be required. Healthcare providers may want to perform tests to determine whether a patient needs a lower dose or should take BARACLUDE less often than once a day.

It is not known if BARACLUDE is safe to use during pregnancy. It is not known if BARACLUDE helps to prevent a pregnant mother from passing HBV to her baby. A pregnant woman and her healthcare provider will need to decide if BARACLUDE is right for her. A woman should not breastfeed if she is taking BARACLUDE.

People should discuss with their healthcare provider all prescription and non-prescription medicines, vitamins, herbal supplements, and other health preparations they are taking or plan to take. BARACLUDE(R) (entecavir) may interact with medicines that leave the body through the kidneys. The most common side effects of BARACLUDE in clinical studies were headache, tiredness, dizziness, and nausea.

This list of side effects is not complete at this time because BARACLUDE is still under study. People should report any new or continuing symptom to their healthcare provider. BARACLUDE should be taken once daily on an empty stomach (at least two hours after a meal and two hours before the next meal). To learn more about BARACLUDE and for Full Prescribing Information, including boxed WARNINGS, please visit www.bms.com.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

BARACLUDE(R) (entecavir) is a trademark of Bristol-Myers Squibb Company.

Full prescribing information for BARACLUDE, including boxed WARNINGS, is available at www.bms.com.

SOURCE Bristol-Myers Squibb Company
CONTACT: Ken Dominski, Communications, +
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
2. Point of Care Strep Tests Speed Treatment, Lower Costs
3. Rapid HIV Testing Increases Possibility of Treatment
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:12/2/2008)...ire/ -- Horizon Therapeutics, Inc., a,privately h...t two pivotal,Phase 3 trials evaluating its lead ...ll primary endpoints. HZT-501, a novel, proprietar...ofen and famotidine, demonstrated a,statistically...roidal,anti-inflammatory drug (NSAID)-induced upp...
(Date:12/1/2008)...c. 2 A study has found ...chnique for imaging the breast, is not affected by...s, two factors that limit the effectiveness of sta...ults will be presented today at the annual meeting...A). , , "The ability of PEM to detect canc...
(Date:12/1/2008).../ -- S*BIO Pte Ltd today announced the initiation ...and orally-active JAK2 inhibitor, in leading medic...idiopathic myelofibrosis (CIMF). , , The t...bility of SB1518 in patients with CIMF and is expe... of the study will assess the safety profile and e...
(Date:12/1/2008)...1 gene is a two-way switch that, if turned off, ca...d so that they lose their identity and become more...Tenn., Dec. 1 Scientis...iscovered that a certain differentiated cell type ...s the constant expression of a gene called Prox1 ...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 1Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 1SI International Awarded 244 Million Army HRsolutions Task Order 3781 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 1CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 3CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 4
(Date:12/2/2008)... 2 MedPro Imaging, a premier provi...ounced the appointment of three,new ultrasound sa...ressive,expansion. The company also announced th...ties due to substantial growth throughout 2008. K...esident of Sales and Marketing in,February of thi...
(Date:12/2/2008)...ford researchers has developed a prototype blood s...ream in early stages of the disease, potentially a...roved chances of survival. , The system based on...iated proteins in a blood serum sample in less tha...existing commercial devices. In fact, the device, ...
(Date:12/2/2008)...ewswire/ -- MedCommons announces integration of it...rchive Solution for Healthcare,Organizations. The...,Organizations provides a modular DICOM-compliant ...s patient information, including medical images fr...ent-centric archive. The,integration with the Med...
(Date:12/2/2008)...with FDA in Early to Mid-2009 , , WARREN, N...ers of PharmFilm(R) technology and a drug delivery...maceutical products, and Strativa Pharmaceuticals,...utical Companies, Inc. (NYSE: PRX ), today annou...quivalence studies for a thin film formulation of ...
Breaking Medicine News(10 mins):Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:Stanford blood scanner detects even faint indicators of cancer 2Health News:Stanford blood scanner detects even faint indicators of cancer 3Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3
...uses genetic damage// in the developing fetus, say...ing during pregnancy causes genetic damage in the ...ephen G. Grant, Ph.D., associate professor of envi...health in the University of Pittsburgh Graduate Sc...
... by illnesses due to exposure to //pesticides have... to 2002, reports a research in the recent issue o...ronment is a health risk facing children and schoo...n the article states. Pesticides continue to be us...
...on (IMA) has today warned its members// all over t... dealing with patients who suffer from bullet, kni...oist violence taking place in the neighboring coun...affarpur district was arrested in May for treating...
...be used successfully to treat heart attacks//. Res...edicine had showed that it is possible to treat th...wo months, stem cells harvested from another pig?s...mal?s damaged heart restored heart function and re...
Other Medicine News:Health News:Exposure to Pesticides in Schools Produces Illnesses Among Employees, Students 2Health News:Stem Cell Therapy For Treating Heart Attacks 2
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches.
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches.
Straight shafts with 7 mm tying platform. Flat serrated handle with dull titanium finish. Overall length 4.5 inches.
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches.
Medicine Products: